Trials / Completed
CompletedNCT00002212
A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (planned)
- Sponsor
- Ligand Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe and effective to give Targretin capsules to patients with AIDS-related Kaposi's sarcoma (KS).
Detailed description
This is a multicenter, open-label study to evaluate the safety and efficacy of Targretin capsules in patients with AIDS-related KS. NOTE: The daily dose may be reduced as necessary for toxicity management.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bexarotene |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002212. Inclusion in this directory is not an endorsement.